UCB NORDIC A/S: Financial statements 2024
CVR: 26688949
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
UCB NORDIC A/S (CVR 26688949) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 84,780,000 and a net result of DKK 5,226,000 compared with DKK 3,888,000 the year before. That is an increase of 26.7% compared with the year before. Equity in the 2024 report amounted to DKK 17,333,000. The solvency ratio was 21.9%. The company had 43 employees in the financial year.
- Gross Profit
- DKK 84,780,000
- Profit/Loss
- DKK 5,226,000
- Equity
- DKK 17,333,000
- Total Assets
- DKK 79,081,000
- Employees
- 43
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 84.8M | 5.2M | 17.3M | 43 |
| 2023 | - | 66.9M | 3.9M | 16.1M | 42 |
| 2022 | - | 61.5M | 4M | 15.1M | 40 |
| 2021 | - | 60.5M | 3M | 14.1M | 40 |
| 2020 | - | 46.2M | 3.7M | 11.1M | 31 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
UCB NORDIC A/S has published its annual report for 2023. Gross profit came to DKK 66,895,000, and the net result was DKK 3,888,000.
About UCB NORDIC A/S
UCB NORDIC A/S is a Danish company of the type Aktieselskab based in København S, founded in 2002. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named UCB NORDICS ApS and CELLTECH NORDIC ApS. The management consists of Mari-Ann Retz. The board consists of Laura Ann Byram (chair), Christina Dyreborg Jeppesen and Jaana Mattila. The company is owned by UCB Pharma SA. The company has 48 employees (2026). In 2025, the company reported a gross profit of DKK 88,278,000 and a net result of DKK 6,014,000 compared with DKK 5,226,000 the year before. Equity in the 2025 report amounted to DKK 18,047,000.